Faruqi & Faruqi Investigation: Synergetics USA, Inc.

Faruqi & Faruqi, LLP Announces the Investigation of Synergetics USA, Inc. (SURG) Over the Proposed Sale of the Company to Valeant Pharmaceuticals

Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Synergetics USA, Inc. (“Synergetics” or the “Company”) (NASDAQ:SURG) for potential breaches of fiduciary duties in connection with the sale of the Company to Valeant Pharmaceuticals for approximately $166 million in a cash transaction.
The Company’s stockholders will only receive $6.50 for each share of Company common stock they own. However, the offer is virtually no premium over the 52-week high.
If you own common stock in Synergetics and wish to obtain additional information and protect your investments free of charge, please fill out the form below or contact F&F's Juan E. Monteverde, Esq. either via e-mail at jmonteverde@faruqilaw.com or by telephone at (877) 247-4292 or (212) 983-9330.

Logo Twitter Facebook LinkedIn Google+